DexCom, Inc. announced that it has received CE Mark approval for the SEVEN(R) PLUS continuous glucose monitoring system, enabling commercialization of the system in the European Union and the countries in Asia and Latin America that recognize the CE Mark.
The SEVEN PLUS is DexCom's third generation device designed to help people with diabetes better manage their diabetes and control their glucose levels. Widely recognized as one of the leading causes of death and disability globally, diabetes is a chronic disease with no known cure that afflicts an estimated 246 million people worldwide, according to the International Diabetes Federation. Diabetes is a leading cause of adult blindness, end stage kidney failure and lower limb amputations. People suffering from diabetes are also more significantly at risk for cardiovascular disease and stroke.
Terrance H. Gregg, DexCom's President and Chief Executive Officer said, We are pleased to have CE Mark approval for the SEVEN PLUS and we look forward to working with physicians, nurses and diabetes educators to bring this important technology to patients around the world.
